Like fud said,if they make an offer it will just push all the other potential suitors to the table,unless they just pay up huge,but all these big Pharmas have major cheddar.I`d like to see them sell only the Arikace for the best offer and keep Iplex.Then use the capital to buy something else,while they`re waiting for 2018 and Iplex to be free and clear of the settlements.Then Lewis and the rest of the board still have jobs and we have more potential for shareholders.
$2 billion would assume peak use of Arikace by about 15,000 Cystic Fibrosis patients (with no other use).
An added bonus would be that the acquisition would catapult the buyer into pole position to supply the first patient-friendly therapy for the 2,000,000,000 people Worldwide estimated to be carrying Latent TB infection.
My gut feeling is that the buyout price could be nearer $3 billion.
This volume today sends a fairly clear message that either something is about to be announced (partnership?) or that the analysts who have either reiterated or increased their targets have developed a strong following. Anyone who listened to the cc had to be impressed by the Q&A and particularly by Mr. Lewis' excitement.